Cort

Recent Posts

Benchmarking deal terms & formulating negotiating positions for AI discovery company

Project Challenge: Our client was a company on which we had conducted due diligence for an investor approached us for support with a potential deal with an AI discovery company. The concept was to...
Learn More

Scouting for metabolic disease assets to license

Challenge: A venture capital portfolio company developing small molecule therapeutics for metabolic/obesity indications had made the strategic decision to supplement their internal product pipeline...
Learn More

Assessing the clinical development & regulatory pathway for a Phase 3 gene therapy product

Challenge Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The company was considering a...
Learn More

Clinical due diligence on a company targeting CNS indications

Challenge A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the...
Learn More

Viral vector manufacturing landscape and bottlenecks

Challenge: A national biomedical research agency requested Alacrita’s support with (1) a technical assessment of the agency’s own internal capabilities in AAV manufacturing, (2) a global landscape of...
Learn More

Assessing a new inhalation device and assisting with partnering

Challenge: A medical device company has developed a nebulizer system for pulmonary delivery that can produce droplets below 1.5µm diameter. Initial clinical evaluations of demonstrator compounds used...
Learn More

Clinical and regulatory support for respiratory delivery specialist

Challenge: A respiratory delivery specialist company was looking at established drugs to assess the attractiveness and risks of developing inhaled or intranasal formulations of selected molecules. It...
Learn More

Valuation of a radiolabeled peptide for diagnosis of pulmonary diseases

Challenge: In preparation for fundraising, a biotech company developing a clinical stage radiolabeled peptide to diagnose pulmonary diseases required an independent valuation of its technology in...
Learn More

Valuation of Rx and OTC products for an investor

Challenge: An investor and asset manager was considering an investment in a European biotech company with one development product for hemophilia and another approved OTC product in an unrelated...
Learn More

Primary market research and patient segmentation mapping in myelofibrosis

Challenge: A venture-backed US biotech company was developing a preclinical biologic for haematological indications and wished to quantify the commercial opportunity for the product in treating...
Learn More

Opportunity mapping for hemojuvelin antibody

Challenge: A US-based biotech company developing a novel biologic which impacts iron metabolism, wanted help deciding which disease and patient groups would make the best lead indication for...
Learn More

Developing a revenue model for an AI application for GI Imaging

Challenge: Our client was a medical solutions provider specialising in AI applications applied to real-time analysis of medical imagery to provide clinicians with real-time decision-making...
Learn More